184 related articles for article (PubMed ID: 38203388)
21. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
22. Panels of mRNAs and miRNAs for decoding molecular mechanisms of Renal Cell Carcinoma (RCC) subtypes utilizing Artificial Intelligence approaches.
Hosseiniyan Khatibi SM; Ardalan M; Teshnehlab M; Vahed SZ; Pirmoradi S
Sci Rep; 2022 Sep; 12(1):16393. PubMed ID: 36180558
[TBL] [Abstract][Full Text] [Related]
23. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA profiles classify papillary renal cell carcinoma subtypes.
Wach S; Nolte E; Theil A; Stöhr C; T Rau T; Hartmann A; Ekici A; Keck B; Taubert H; Wullich B
Br J Cancer; 2013 Aug; 109(3):714-22. PubMed ID: 23799849
[TBL] [Abstract][Full Text] [Related]
26. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
27. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
[TBL] [Abstract][Full Text] [Related]
28. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
30. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.
Lamers F; Schild L; Koster J; Versteeg R; Caron HN; Molenaar JJ
Eur J Cancer; 2012 Mar; 48(5):763-71. PubMed ID: 22088485
[TBL] [Abstract][Full Text] [Related]
31. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
32. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
33. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.
Hong SH; Hwang HJ; Son DH; Kim ES; Park SY; Yoon YE
FEBS Open Bio; 2023 Apr; 13(4):724-735. PubMed ID: 36808829
[TBL] [Abstract][Full Text] [Related]
35. YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells.
Woo SM; Min KJ; Seo BR; Kwon TK
Oncotarget; 2016 Sep; 7(38):61520-61532. PubMed ID: 27528031
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
37. The Value of Contrast-Enhanced Ultrasound in Diagnosing Small Renal Cell Carcinoma Subtypes and Angiomyolipoma.
Cao H; Fang L; Chen L; Zhan J; Diao X; Liu Y; Lu C; Zhang Z; Chen Y
J Ultrasound Med; 2022 Jun; 41(6):1415-1423. PubMed ID: 34499770
[TBL] [Abstract][Full Text] [Related]
38. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
Douglas ML; Richardson MM; Nicol DL
Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
40. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
